Abstract
Objective
Interindividual variability in plasma concentrations of nicotine and its proximate metabolite, cotinine, is considerable during smoking and transdermal nicotine treatment, even among individuals taking in nominally similar doses of nicotine. This report explores the determinants of this variability and the utility of baseline (smoking) plasma concentrations to predict concentrations during transdermal nicotine treatment.
Methods
Data were analysed from a smoking cessation study (n = 466), and from a pharmacokinetic study (n = 12). Multiple regression models examined the relationships of plasma concentrations to individual characteristics such as smoking pattern, absorbed dose of nicotine, and pharmacokinetic parameters.
Results
Plasma concentrations of nicotine and cotinine were highly variable in both studies. Indirect estimates of plasma clearance (baseline plasma concentration divided by cigarettes per day) together with other factors could account for 18 to 33% of the variability during transdermal nicotine treatment in the smoking cessation study. In contrast, 75 to 99% was accounted for by direct measurements of plasma clearances and systemic dose of nicotine in the pharmacokinetic study.
Conclusion
Plasma concentrations of nicotine and cotinine during transdermal nicotine treatment are poorly predicted by clinical history or baseline plasma concentrations. This is a result of inadequate characterisation of highly variable individual pharmacokinetic parameters and absorbed dose of nicotine. Considering the interindividual variability of plasma nicotine and cotinine concentrations together with the lack of clinical end-points for transdermal nicotine dosing, it seems logical to investigate the utility of a therapeutic drug monitoring approach for transdermal nicotine treatment — particularly for high dose regimens (> 22 mg per 24 hours).
Similar content being viewed by others
References
Benowitz NL, Jacob III P, Yu L, Talcott R, Hall S, Jones RT (1986) Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow — but not low-yield cigarettes. JAMA 256: 241–246
Coultas DB, Stidley CA, Samet JM (1993) Cigarette yields of tar and nicotine and markers of exposure to tobacco smoke. Am Rev Resp Dis 148: 435–40
Nørregaard J, Tønnesen P, Peterson L (1993) Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med 22: 261–271
Tønnesen P, Nørregaard J, Simonsen K, Säwe U (1991) A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325: 311–15
Stapleton JA, Russell MAH, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U (1995) Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 90: 31–2
Benowitz NL, Jacob III P (1994) Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharm Ther 56: 483–193
Benowitz NL, Jacob III P (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35: 499–504
Hurt RD, Dale LC, Offord KP et al. (1993) Serum nicotine and cotinine levels during nicotine patch therapy. Clin Pharm Ther 54: 98–106
Hurt RD, Dale LC, Fredrickson PA et al. (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: one year outcome and percentage of nicotine replacement. JAMA 271: 595–600
Benowitz NL, Jacob III P, Olsson P, Johansson C-J (1992) Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption. Clin Pharm Ther 52: 223–230
Sachs DP, Benowitz NL, Bostrum AG, Hansen MD (1995) Percent serum replacement and success of nicotine patch therapy. Am J Respir Crit Care Med 151: A688
Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ (1994) A prospective study of factors predicting smoking cessation using transdermal nicotine therapy. BMJ 309: 842–846
Drummer OH, Horomidis S, Kourtis S, Syrjanen ML, Tippett P (1994) Capillary gas Chromatographic drug screening for use in forensic toxicology. J Analytical Toxicol 18: 134–138
Jacob III P, Wilson M, Benowitz NL (1981) Improved gas Chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatog, Biomed Applications 222: 61–70
Jacob III P, Yu L, Wilson M, Benowitz NL (1991) Selected ion monitoring method for determination of nicotine, cotinine, and deuterium-labelled analogues: absence of an isotope effect in the clearance of (s)-nicotine-3’,3’-d2 in humans. Biol Mass Spectrometry 20: 247–252
Therapeutic Goods Administration (1991) Good Clinical Research Practice Guidelines. Australian Department of Community Services and Health, Canberra.
Gourlay SG, McNeil JJ (1990) Antismoking Products.Med J Aust 153: 699–707
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Brit J Addict 86: 1119–1127
Gori GB, Lynch CJ (1985) Analytical cigarette yields as predictors of smoke bioavailability. Regulatory Toxicol & Pharmacol 5: 314–326
Russell MAH, Jarvis M, Iyer R, Feyerabend C (1980) Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. Br Med J i: 972–976
Transdermal nicotine study group. Transdermal nicotine for smoking cessation. JAMA 266: 3133–3138
Jorenby DE, Smith SS, Fiore MC et al. (1995) Varying nicotine patch dose and type of smoking cessation counseling. JAMA 274: 1347–1352
Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR (1995) High dose nicotine patch therapy: percentage of replacement and smoking cessation. JAMA 274: 1353–1358
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gourlay, S.G., Benowitz, N.L., Forbes, A. et al. Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment. Eur J Clin Pharmacol 51, 407–414 (1997). https://doi.org/10.1007/s002280050222
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002280050222